Table 1.
Demographic and hematologic characteristics of 78 patients with MPNs.
Table 2.
Frequency of JAK2 V617F mutation in Korean MPNs patients.
Table 3.
Quantitation of JAK2 mutant by real time PCR and pyrosequencing from the patients with JAK2 V617F mutation.
Figure 1.
Allelic expression imbalance of JAK2 V617F mutation.
Pyrosequencing assay for the detection of JAK2 1849G>T mutation was applied in genomic DNA and corresponding cDNA samples from patients with ET (A) and PV (B and C). Reversed pyrogram disclosed allelic expression imbalance (amplification in cDNA) of the JAK2 mutant.
Figure 2.
Ratio of the JAK2 mutant allelic load of gDNA and cDNA.
Amplification of JAK2 mutant allele was observed in all MPN patients. The ratio of JAK2 mutant from genomic and cDNA disclosed markedly difference from MPN patients (n = 57) with the JAK2 V617F mutation. Allelic expression imbalance of JAK2 V617F mutation is associated with MPN phenotypes.
Figure 3.
Proportion of the JAK2 V617F mutant according to treatment response in 15 PV patients with the JAK2 V617F mutation.
JAK2 mutant load predicted treatment response and strategy at diagnosis.